Treatment of the 3D organoid cell population with SM-3 resulted in a significant reduction in the levels of stem cell markers (CD133 and CD44) and stem cell transcription factors (OCT-4 and SOX2) in lung cancer organoids (Fig. 9E and F). This evidence concerns the gene SOX2 and lung carcinoma.